Arcus Biosciences Inc. is a clinical-stage biopharmaceutical company that discovers and develops next-generation immunotherapies for the treatment of cancer and inflammatory diseases. The company's clinical pipeline features multiple investigational medicines, including domvanalimab (an anti-TIGIT antibody), zimberelimab (an anti-PD-1 antibody), casdatifan (a HIF-2a inhibitor), and quemliclustat (a CD73 inhibitor). Arcus employs a multi-mechanism approach, designing small molecules and monoclonal antibodies to work in complementary combinations to reverse tumor-associated immunosuppression. A defining characteristic of the company's business model is its extensive collaboration network, highlighted by a 10-year partnership with Gilead Sciences, which holds exclusive options to co-develop and co-commercialize Arcus's programs. The company also maintains strategic alliances with AstraZeneca and Taiho Pharmaceutical to advance its clinical trials globally.
